SEQUENTIAL GN-RH SUPERAGONIST AND MEDROXYPROGESTERONE ACETATE TREATMENT OF UTERINE LEIOMYOMATA

被引:22
作者
BENAGIANO, G
MORINI, A
ALEANDRI, V
PICCINNO, F
PRIMIERO, FM
ABBONDANTE, G
ELKINDHIRSCH, K
机构
[1] UNIV ROME LA SAPIENZA,INST OBSTET & GYNECOL 1,I-00185 ROME,ITALY
[2] BAYLOR UNIV,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030
关键词
Buserelin; Gn-RH analogs; Medroxyprogesterone acetate; Pharmacologic treatment of fibroids;
D O I
10.1016/0020-7292(90)90520-U
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A group of 48 women with symptomatic leiomyomata were treated during 6 months with the short-acting Gn-RH superagonist analog buserelin. The first (group C) was followed up for an additional six months of no medication. The second (group M) was treated for 6 additional months with medroxyprogesterone acetate (MPA) at doses decreasing from 200 to 25 mg/day. Buserelin therapy significantly decreased uterine size (P < 0.001) in all patients, the average final volume being 48.5% of the original (from 262 ± 147 ml to 127 ± 85.4 ml). In group C there was a significant (P < 0.001) re-growth during the post-treatment observation period (from 120 ± 81.0 ml to 198 ± 77.2 ml); a significant (P < 0.01) re-growth was also observed in group M during MPA medication (from 132 ± 77.2 ml to 170 ± 96.0 ml). The agonist had also a marked effect on fibroids: on average they decreased from 75.1 ± 74.3 ml to 24.7 ± 23.3 ml (P < 0.025). In group C during the post-buserelin period of observation without treatment, there was a significant re-growth from 23.7 ± 21.6 ml to 47.7 ± 27.5 ml (P < 0.001), whereas in group M treatment with MPA prevented any significant re-growth (from 25.6 ± 24.8 to 30.6 ± 32.9 ml; P > 0.3). © 1990.
引用
收藏
页码:333 / 343
页数:11
相关论文
共 26 条
[1]  
Anderson, Peck, Clark, Estrogen-induced uterine responses and growth: Relationship to receptors-estrogen binding by uterine nuclei, Endocrinology, 96, (1975)
[2]  
Andreyko, Blumenfeld, Marshall, Monroe, Hricak, Jaffe, Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging, Am J Obstet Gynecol, 158, (1988)
[3]  
Baird, West, Medical management of fibroids, Br Med J, 296, (1988)
[4]  
Baird, Bramley, Hawkins, Lumsden, West, Effect of treatment with LHRH analogue zoladex on binding of oestradiol, progesterone and epidermal growth factor to uterine fibromyomata, Hormone Res, 32, (1989)
[5]  
Buttram, Reiter, Uterine leiomyomata: etiology, symptomatology, and management., Fertil Steril, 36, (1981)
[6]  
Corbin, Beattie, Tracy, Jones, Foell, Yardley, Rees, The anti-reproductive pharmacology of LHRH and agonist analogues, Int J Fertil, 23, (1978)
[7]  
Crona, Enk, Samsioe, Silfverstalpe, Skryten, High-dose depot-medroxyprogesterone acetate (DMPA) — effects on lipid and lipoprotein metabolism, European Journal of Obstetrics & Gynecology and Reproductive Biology, 16, (1983)
[8]  
Fahraeus, Sydsjo, Wallentin, Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate., Fertil Steril, 45, (1986)
[9]  
Filicori, Hall, Loughlin, Rivier, Vale, Crowley, A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue, Am J Obstet Gynecol, 147, (1983)
[10]  
Friedman, Barbieri, Doubilet, A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprosterone acetate in the treatment of leiomyomata uteri, Fertil Steril, 49, (1988)